Sign In
Buy ARDX
$6.18
-0.190 (-2.98%)
At Close: Jun 23, 2026
Ardelyx Stock Plummets As Review Period For Tenapanor US Application Pushed By 3 Months
06:34am, Friday, 30'th Apr 2021
The FDA has extended the Prescription Drug User Fee Act (PDUFA) date for Ardelyx Inc's (NASDAQ: ARDX) tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 16'th Apr 2021
FREMONT, Calif. and WALTHAM, Mass.
Implied Volatility Surging for Ardelyx (ARDX) Stock Options
09:04am, Friday, 16'th Apr 2021
Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.
Why Ardelyx Stock Soared Today
03:00pm, Wednesday, 14'th Apr 2021
The company's Japanese partner initiated pivotal late-stage studies of Ardelyx's lead candidate.
Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan
08:00am, Wednesday, 14'th Apr 2021
FREMONT, Calif. and WALTHAM, Mass.
Ardelyx Announces Upcoming Data Presentation at ISN World Congress of Nephrology 2021
08:00am, Monday, 12'th Apr 2021
FREMONT, Calif. and WALTHAM, Mass.
Ardelyx (ARDX) Stock Jumps 6.8%: Will It Continue to Soar?
09:51am, Thursday, 01'st Apr 2021
Ardelyx (ARDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength do
FREMONT, Calif. and WALTHAM, Mass.
5 Sizzling Stocks to Buy Under $10 With Sizable Upside Potential
06:05am, Saturday, 27'th Mar 2021
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Ardelyx (ARDX) Reports Q4 Loss, Misses Revenue Estimates
10:37am, Monday, 08'th Mar 2021
Ardelyx (ARDX) delivered earnings and revenue surprises of -23.08% and -3.26%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today the Canadian commercial avail
Ardelyx Before The April PDUFA
05:06pm, Saturday, 27'th Feb 2021
Ardelyx has a PDUFA on April 29 for tenapanor in hyperphosphatemia in CKD patients. Data has been good, and there's an unmet medical need.
Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
01:39pm, Friday, 26'th Feb 2021
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Notable Insider Buys Of the Past Week: Avis Budget, Biotech IPOs And More
01:46pm, Saturday, 12'th Dec 2020
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying ca
Week 50 MDA Breakout Forecast - December: Short-Term Picks To Give You An Edge
11:35am, Saturday, 05'th Dec 2020
Two new breakout stocks for Week 50 with better than 10% short-term upside potential. This past week two out of four stocks gained over 10% led by peak gains in AQB +103.3% and OPRX +12.7% closing wit
